Is Akebia Therapeutics, Inc. (AKBA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 14.0% / 30% | 15.2% / 30% | 10.1% / 30% | 0.51% / 5% | ✓ HALAL |
| DJIM | 14.0% / 33% | 15.2% / 33% | 10.1% / 33% | 0.51% / 5% | ✓ HALAL |
| MSCI | 21.6% / 33% | 23.5% / 33% | 15.6% / 33% | 0.51% / 5% | ✓ HALAL |
| S&P | 14.0% / 33% | 15.2% / 33% | 10.1% / 33% | 0.51% / 5% | ✓ HALAL |
| FTSE | 21.6% / 33% | 23.5% / 33% | 15.6% / 50% | 0.51% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 82.9% | |
| Operating Margin | -10.5% | |
| Net Margin | -2.3% | |
| Return on Assets (ROA) | 5.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $68M |
| Free Cash Flow | $60M |
| Total Debt | $52M |
| Debt-to-Equity | 609.6 |
| Current Ratio | 1.6 |
| Total Assets | $377M |
Price & Trading
| Last Close | $1.39 |
| 50-Day MA | $1.36 |
| 200-Day MA | $2.38 |
| Avg Volume | 3.3M |
| Beta | 0.4 |
|
52-Week Range
$1.14
| |
About Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Purification Calculator
As a halal stock with 0.51% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Akebia Therapeutics, Inc. (AKBA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Akebia Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Akebia Therapeutics, Inc.'s debt ratio?
Akebia Therapeutics, Inc.'s debt ratio is 14.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 21.6%.
Does Akebia Therapeutics, Inc. require dividend purification?
Yes, Akebia Therapeutics, Inc. has an impermissible income ratio of 0.51%, which means 0.51% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Akebia Therapeutics, Inc.'s key financial metrics?
Akebia Therapeutics, Inc. has a market capitalization of $359M, and revenue of $236M. The company maintains a gross margin of 82.9% and a net margin of -2.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.